Skip to main content

NCNA

Stock
Health Care
Biotechnology

Performance overview

NCNA Price
Price Chart

Forward-looking statistics

Beta
1.36
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees29
Market cap$6.9M

Fundamentals

Enterprise value$6.7M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity4.14

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$5.15
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$12M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth+3.6
Credit-1.2
Liquidity-2.1
Inflation+4.2
Commodities+0.9
Interest Rates-3.8

Valuation

Dividend yield0.00%
PEG Ratio-0.01
Price to sales
P/E Ratio-0.01
Enterprise Value to Revenue
Price to book0.08

Upcoming events

Next earnings dayMarch 21, 2025
Next dividend day
Ex. dividend day

News

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Zacks Investment Research (September 17, 2024)
Why NuCana Shares Are Rising Today?

Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European Patent 2955190 through their sales of Sovaldi, Harvoni, Vosevi and.

Benzinga (July 11, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free